Kidney Disease, End-Stage
11
4
5
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
18%
2 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (11)
Ellipsys Vascular Access System Post Market Surveillance (PS) Study
Rutgers University Study of the Genetics of Kidney Disease
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
Low-Dose Apixaban Added to Standard Heparin Lock Versus Heparin Lock Alone to Prevent Tunneled Hemodialysis Catheters Dysfunction (APICATH-HD)
Virtual Home-based Physical Pre-habilitation in Kidney Transplant Candidates
PATH-03 Paraguay Feasibility Study
Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant
TreaT-Assay: the New Frontier for the Diagnosis of Acute Rejection in Kidney Transplantation
Evaluating the Use of the Qidni/D Hemodialysis System by Subjects With End-Stage Renal Disease
Electronic Patient-Reported Outcomes in Clinical Kidney Practice (ePRO Kidney)
Determination In-vivo KUF for Diacap Pro Hemodialyser